CRISPR Therapeutics Presents New Preclinical Data for CTX460™ Demonstrating In Vivo Gene Correction of Alpha-1 Antitrypsin Deficiency (AATD) Utilizing Novel SyNTase™ Editing PlatformGlobeNewsWire • 10/10/25
CRISPR Therapeutics (CRSP) Surges 8.7%: Is This an Indication of Further Gains?Zacks Investment Research • 10/09/25
CRISPR Therapeutics to Present Preclinical Data on Alpha-1 Antitrypsin Deficiency (AATD) Utilizing Novel SyNTase Gene Editing Technology at the European Society of Gene and Cell Therapy (ESGCT) 2025 Annual CongressGlobeNewsWire • 10/01/25
CRSP & Sirius Begin Dosing in Thromboembolic Disorder Study in EUZacks Investment Research • 09/23/25
Crispr Therapeutics: Why Stock Fell On Q2 Earnings, And Why We're Now Back On TrackSeeking Alpha • 09/17/25
Wall Street Analysts See CRISPR Therapeutics (CRSP) as a Buy: Should You Invest?Zacks Investment Research • 09/11/25
Cathie Wood Goes Bargain Hunting: She Just Bought 2 Stocks That Wall Street Thinks Will Climb 50% and 190%The Motley Fool • 09/11/25
CRISPR Therapeutics to Present Late-Breaking Data at the American Heart Association (AHA) Scientific Sessions 2025GlobeNewsWire • 09/09/25
CRISPR Therapeutics AG (CRSP) Presents At Morgan Stanley 23rd Annual Global Healthcare Conference TranscriptSeeking Alpha • 09/09/25
CRISPR Therapeutics AG (CRSP) Presents at H.C. Wainwright 27th Annual Global Investment Conference TranscriptSeeking Alpha • 09/09/25
CRSP vs. BEAM: Which Gene Editing Stock Holds More Potential Right Now?Zacks Investment Research • 08/28/25
CRISPR Therapeutics Gains 41.4% in 3 Months: How to Play the StockZacks Investment Research • 08/21/25
Here's How This Forgotten Healthcare Stock Could Generate Life-Changing ReturnsThe Motley Fool • 08/17/25